Attached files
| file | filename |
|---|---|
| EXCEL - IDEA: XBRL DOCUMENT - PRECIGEN, INC. | Financial_Report.xls |
| EX-32.2 - EXHIBIT 32.2 - PRECIGEN, INC. | xon-20141231exx322.htm |
| EX-23.1 - EXHIBIT 23.1 - PRECIGEN, INC. | xon-20141231exx231.htm |
| EX-32.1 - EXHIBIT 32.1 - PRECIGEN, INC. | xon-20141231exx321.htm |
| EX-31.2 - EXHIBIT 31.2 - PRECIGEN, INC. | xon-20141231exx312.htm |
| EX-21.1 - EXHIBIT 21.1 - PRECIGEN, INC. | xon-20141231exx211.htm |
| 10-K - 10-K - PRECIGEN, INC. | xon-20141231x10k.htm |
| EX-31.1 - EXHIBIT 31.1 - PRECIGEN, INC. | xon-20141231exx311.htm |
Exhibit 23.2
Consent of independent registered public accounting firm
We consent to the incorporation by reference in Registration Statements on Form S-8 (File No. 333-190614) and Form S-3 (No. 333-198598) of Intrexon Corporation of our report dated February 26, 2015, relating to our audit of the financial statements of ZIOPHARM Oncology, Inc., which appears in the Annual Report on Form 10-K of Intrexon Corporation for the year ended December 31, 2014.
/s/ McGladrey LLP
Boston, Massachusetts
March 2, 2015